Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001952142-24-000002
Filing Date
2024-02-12
Accepted
2024-02-12 18:27:26
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 142972
2 JOINT FILING AGREEMEMT JOINT_FILING_AGREEMENT.pdf EX-1 98441
  Complete submission text file 0001952142-24-000002.txt   280644
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Subject) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: SCHEDULE 13G | Act: 34 | File No.: 005-86249 | Film No.: 24621860
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 520 MADISON AVE 19TH FLOOR NEW YORK NY 10022
Business Address 520 MADISON AVE 19TH FLOOR NEW YORK NY 10022 (212) 540-4099
StemPoint Capital LP (Filed by) CIK: 0001952142 (see all company filings)

EIN.: 920402540 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G